Performance History
| Key Stats | |
|---|---|
| Open | $8.41 |
| Prev. Close | $7.35 |
| EPS | -1.15 |
| Dividend | Non-Dividend |
| Next Earnings Date | - |
| Dividend Yield % | - |
| Market Cap | $4.97B |
| PE Ratio | - |
| LOW | HIGH | |
|---|---|---|
| Day Range | 8.12 | 10.53 |
| 52 Week Range | 1.25 | 10.53 |
| Ratios | |
|---|---|
| P/B Ratio | 0.00 |
| Revenue | - |
| Operating M. % | -60,792.80% |
| Earnings | $0.00 |
| Earnings Growth % | -39.75% |
| EBITDA Margin % | - |
| ROE % | 0.00% |
| EPS | -1.15 |
Score Breakdown
Welcome to Stocklytics
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
All Score 65 / 100 is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.
| IBRX | MARKET | |
|---|---|---|
| Value | 30 | 38 |
| Quality | 46 | 40 |
| Ownership | 37 | 17 |
| Growth | 77 | 44 |
| Dividends | - | 37 |
ImmunityBio's Price growth average in the last 3 years of 42.74% is great compared to market average of 6.07%. This indicates IBRX could be a good value stock.
Financial Forecast
AI Price Prediction
Analyst Ratings
Correlated Companies
About ImmunityBio (IBRX)
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Richard Gerald Adcock
- Headquarters
- San Diego
- Employees
- 683
- Exchange
- NASDAQ
Keep an eye on ImmunityBio
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Frequently Asked Questions
What is ImmunityBio's (IBRX) price per share?
The current price per share for ImmunityBio (IBRX) is $8.99. The stock has seen a price change of $1.64 recently, indicating a 22.31% change. This reflects the stock's recent market performance and investor sentiment.
What is the 52-week high and low for ImmunityBio (IBRX)?
For ImmunityBio (IBRX), the 52-week high is $10.53, which is 17.13% from the current price. The 52-week low is $1.25, the current price is 619.2% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
Is ImmunityBio (IBRX) a growth stock?
ImmunityBio (IBRX) has shown an average price growth of -5.59% over the past three years. It has received a score of 45 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying ImmunityBio as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
What is ImmunityBio (IBRX) stock price performance year to date (YTD)?
As of the latest data, ImmunityBio (IBRX) has a year-to-date price change of 71.56%. Over the past month, the stock has experienced a price change of 68.98%. Over the last three months, the change has been 146.3%. Over the past six months, the figure is 191.88%.
Is ImmunityBio (IBRX) a profitable company?
ImmunityBio (IBRX) has a net income of -$583.2M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -60.79K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$361.36M. Furthermore, the EBITDA is -$342.85M.
What is the market capitalization of ImmunityBio (IBRX)?
ImmunityBio (IBRX) has a market capitalization of $4.98B. The average daily trading volume is 17.38M, indicating the stock's liquidity and investor engagement.
News
Netflix’s Profitability Skyrocketed by 577% in Five Years
Will Meta and Alphabet Benefit from TikTok’s Ban?
US-China Trade Deficit Shrinks by 25% to $279B, Hitting Lowest Point Since 2010
Live Streaming Ecommerce in China to Become a Trillion-Dollar Industry by 2026
Meta Platforms Stock: Is it a Buy on the Dip?
Natural Language Processing Market Size to Cross the $150B Mark by 2030
Sign up for our newsletter
Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.